AmideBio has leveraged its core BioPure™ technology to pursue a series of therapeutic targets that include, ultrastable and ultraconcentrated insulin for T2 diabetes, glucose responsive insulin for T1 and T2 diabetes, solution stable glucagon for hyperinsulinism and similar orphan indications for which orphan drug designation (ODD) and/or rare pediatric disease designation (RPDD) are applicable. The company is also pursuing the development of diagnostics for early detection of T1 diabetes. The key to these discovery programs is theBioPure™ process which allows rapid candidate peptide production for QSAR studies.
